These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 22035433)

  • 41. Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement.
    Schoels MM; van der Heijde D; Breedveld FC; Burmester GR; Dougados M; Emery P; Ferraccioli G; Gabay C; Gibofsky A; Gomez-Reino JJ; Jones G; Kvien TK; Murakami M; Nishimoto N; Smolen JS
    Ann Rheum Dis; 2013 Apr; 72(4):583-9. PubMed ID: 23144446
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The effect of tocilizumab on preventing relapses in adult-onset Still's disease: A retrospective, single-center study.
    Nishina N; Kaneko Y; Kameda H; Takeuchi T
    Mod Rheumatol; 2015 May; 25(3):401-4. PubMed ID: 25401229
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The role of tocilizumab in the management of rheumatoid arthritis.
    Ash Z; Emery P
    Expert Opin Biol Ther; 2012 Sep; 12(9):1277-89. PubMed ID: 22849354
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical safety of tocilizumab in rheumatoid arthritis.
    Bannwarth B; Richez C
    Expert Opin Drug Saf; 2011 Jan; 10(1):123-31. PubMed ID: 21121872
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Tocilizumab - a novel therapy for non-organ-specific autoimmune diseases.
    Kaly L; Rosner I
    Best Pract Res Clin Rheumatol; 2012 Feb; 26(1):157-65. PubMed ID: 22424201
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Tumour necrosis factor α antagonists in the treatment of rheumatoid arthritis: an immunological perspective.
    Meroni PL; Valesini G
    BioDrugs; 2014 Apr; 28 Suppl 1():S5-13. PubMed ID: 24687234
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE study.
    Yazici Y; Curtis JR; Ince A; Baraf H; Malamet RL; Teng LL; Kavanaugh A
    Ann Rheum Dis; 2012 Feb; 71(2):198-205. PubMed ID: 21949007
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [New approaches to pharmacotherapy for rheumatoid arthritis: perspective for use of tocilizumab (monoclonal antibodies to interleukin-6 receptor)].
    Nasonov EL
    Ter Arkh; 2010; 82(5):64-71. PubMed ID: 20597275
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Serum interleukin 6 before and after therapy with tocilizumab is a principal biomarker in patients with rheumatoid arthritis.
    Shimamoto K; Ito T; Ozaki Y; Amuro H; Tanaka A; Nishizawa T; Son Y; Inaba M; Nomura S
    J Rheumatol; 2013 Jul; 40(7):1074-81. PubMed ID: 23637318
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A case of bilateral trochleitis in adult-onset Still's disease.
    Gutmark R; Eliasieh K; Rivera-Michlig R
    Semin Arthritis Rheum; 2014 Apr; 43(5):689-91. PubMed ID: 24176730
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical pharmacology of tocilizumab for the treatment of patients with rheumatoid arthritis.
    Zhang X; Peck R
    Expert Rev Clin Pharmacol; 2011 Sep; 4(5):539-58. PubMed ID: 22114882
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Biological treatment of rare inflammatory rheumatic diseases].
    Baslund B
    Ugeskr Laeger; 2008 Jun; 170(24):2150-2. PubMed ID: 18565301
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Intravenous tocilizumab: a review of its use in adults with rheumatoid arthritis.
    Dhillon S
    BioDrugs; 2014 Feb; 28(1):75-106. PubMed ID: 24255004
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cutaneous sarcoidosis in a patient with rheumatoid arthritis receiving tocilizumab.
    Shono Y; Kamata M; Takeoka S; Ikawa T; Tateishi M; Fukaya S; Hayashi K; Fukuyasu A; Tanaka T; Ishikawa T; Ohnishi T; Asako K; Kono H; Tada Y
    J Dermatol; 2018 Aug; 45(8):e217-e218. PubMed ID: 29500868
    [No Abstract]   [Full Text] [Related]  

  • 55. Methotrexate use in miscellaneous inflammatory diseases.
    Wilke WS
    Rheum Dis Clin North Am; 1997 Nov; 23(4):855-82. PubMed ID: 9361159
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Anakinra in refractory adult onset Still's disease].
    Vercoutere W; Starmans-Kool M; Peeters RM
    Ned Tijdschr Geneeskd; 2011; 155(18):A2966. PubMed ID: 21466723
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy of tocilizumab in refractory adult-onset Still's disease; report of 2 cases.
    Andrade-Ortega L; Irazoque-Palazuelos F; Muñoz-López S; Rosales-Don Pablo VM
    Reumatol Clin; 2014; 10(3):199-200. PubMed ID: 24076178
    [No Abstract]   [Full Text] [Related]  

  • 58. Biologic agents for rheumatoid arthritis: 2008 and beyond.
    Sweiss NJ; Hushaw LL
    J Infus Nurs; 2009; 32(1 Suppl):S4-17; quiz S19-24. PubMed ID: 19142153
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Therapeutic response of patients with adult Still's disease to biologic agents: multicenter results in Japan.
    Suematsu R; Ohta A; Matsuura E; Takahashi H; Fujii T; Horiuchi T; Minota S; Ishigatsubo Y; Ota T; Takei S; Soejima S; Inoue H; Koarada S; Tada Y; Nagasawa K
    Mod Rheumatol; 2012 Sep; 22(5):712-9. PubMed ID: 22160845
    [TBL] [Abstract][Full Text] [Related]  

  • 60. IL-6 blockers in systemic onset juvenile idiopathic arthritis.
    Barone P; Pignataro R; Garozzo MT; Leonardi S
    Immunotherapy; 2016; 8(1):79-87. PubMed ID: 26642378
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.